Core Laboratories Inc. (NYSE:CLB) Holdings Boosted by Assetmark Inc.

Assetmark Inc. boosted its holdings in Core Laboratories Inc. (NYSE:CLB) by 92.5% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,887 shares of the oil and gas company’s stock after acquiring an additional 1,387 shares during the period. Assetmark Inc.’s holdings in Core Laboratories were worth $43,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the business. Tower Research Capital LLC TRC lifted its position in Core Laboratories by 843.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,284 shares of the oil and gas company’s stock valued at $57,000 after purchasing an additional 2,936 shares during the last quarter. BNP Paribas Financial Markets bought a new stake in Core Laboratories in the 4th quarter valued at about $123,000. KLP Kapitalforvaltning AS bought a new stake in Core Laboratories in the 4th quarter valued at about $149,000. Sherbrooke Park Advisers LLC bought a new stake in Core Laboratories in the 4th quarter valued at about $176,000. Finally, Freestone Grove Partners LP bought a new stake in Core Laboratories in the 4th quarter valued at about $181,000. Institutional investors own 97.81% of the company’s stock.

Core Laboratories Stock Performance

Shares of CLB opened at $10.56 on Tuesday. The firm’s 50 day moving average is $11.83 and its 200-day moving average is $13.51. The stock has a market capitalization of $494.97 million, a P/E ratio of 17.03, a P/E/G ratio of 3.20 and a beta of 1.41. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.27 and a quick ratio of 1.70. Core Laboratories Inc. has a 12-month low of $10.14 and a 12-month high of $21.83.

Core Laboratories (NYSE:CLB) last released its earnings results on Wednesday, July 23rd. The oil and gas company reported $0.19 earnings per share for the quarter, topping the consensus estimate of $0.18 by $0.01. Core Laboratories had a net margin of 5.73% and a return on equity of 14.15%. The business had revenue of $130.16 million for the quarter, compared to the consensus estimate of $129.19 million. During the same period last year, the firm posted $0.22 earnings per share. The firm’s quarterly revenue was down .3% compared to the same quarter last year. Equities research analysts anticipate that Core Laboratories Inc. will post 0.96 EPS for the current fiscal year.

Core Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 25th. Shareholders of record on Monday, August 4th will be paid a $0.01 dividend. The ex-dividend date is Monday, August 4th. This represents a $0.04 dividend on an annualized basis and a yield of 0.4%. Core Laboratories’s payout ratio is 6.45%.

Analyst Ratings Changes

Several analysts recently weighed in on CLB shares. Stifel Nicolaus cut their price objective on shares of Core Laboratories from $13.00 to $12.00 and set a “hold” rating on the stock in a research report on Wednesday, July 16th. Wall Street Zen upgraded shares of Core Laboratories from a “sell” rating to a “hold” rating in a research report on Saturday, July 26th. Finally, Citigroup dropped their price target on shares of Core Laboratories from $16.00 to $13.00 and set a “neutral” rating on the stock in a research report on Tuesday, May 13th.

About Core Laboratories

Core Laboratories Inc provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock and reservoir fluid samples to enhance production and improve recovery of crude oil and gas from its clients' reservoirs.